Abstract
Lianhua Qingwen capsule/granule is an innovative Chinese medicine developed under the guidance of the traditional Chinese medicine (TCM) collateral disease theory. It has the effect of “clearing heat and removing toxin, ventilating the lungs and discharging heat”. In 2003, it was approved as a new drug by the China National Medical Products Administration, through expedited approval during severe acute respiratory syndrome, and now, it has become a representative proprietary Chinese medicine for the treatment of infectious diseases of the respiratory system. Pharmacodynamic studies have revealed that Lianhua Qingwen has broad-spectrum antiviral, antibacterial and anti-inflammatory, antipyretic, cough-relieving, and immunoregulation effects. Clinically it has been used in the treatment of communicable and infectious respiratory diseases such as Coronavirus Disease 2019, influenza, colds, pulmonary infections, etc. and has achieved remarkable curative effects, showing the important clinical guidance of the TCM collateral disease theory.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
